AAV-LRRK2 Gene Therapy IND-Enabling Study Design

AAV-LRRK2 Gene Therapy IND-Enabling Study Design

Background and Rationale

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor dysfunction and eventual disability. Mutations in the LRRK2 gene are the most common genetic cause of familial PD, accounting for up to 40% of cases in certain populations. The G2019S mutation in LRRK2 results in increased kinase activity, leading to neuronal toxicity and cell death. This IND-enabling study represents a comprehensive preclinical development program for AAV-mediated LRRK2 knockdown gene therapy, building upon prior serotype optimization studies that identified the most effective vectors for substantia nigra delivery. The study design encompasses critical regulatory requirements including biodistribution, toxicology, pharmacology, and manufacturing characterization necessary for FDA IND submission. The therapeutic approach utilizes adeno-associated virus vectors engineered with LRRK2-targeting shRNA or antisense constructs to reduce pathogenic LRRK2 expression specifically in affected brain regions.

...

AAV-LRRK2 Gene Therapy IND-Enabling Study Design

Background and Rationale

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor dysfunction and eventual disability. Mutations in the LRRK2 gene are the most common genetic cause of familial PD, accounting for up to 40% of cases in certain populations. The G2019S mutation in LRRK2 results in increased kinase activity, leading to neuronal toxicity and cell death. This IND-enabling study represents a comprehensive preclinical development program for AAV-mediated LRRK2 knockdown gene therapy, building upon prior serotype optimization studies that identified the most effective vectors for substantia nigra delivery. The study design encompasses critical regulatory requirements including biodistribution, toxicology, pharmacology, and manufacturing characterization necessary for FDA IND submission. The therapeutic approach utilizes adeno-associated virus vectors engineered with LRRK2-targeting shRNA or antisense constructs to reduce pathogenic LRRK2 expression specifically in affected brain regions. Key study components include dose-ranging efficacy studies in relevant animal models, comprehensive safety assessment including genotoxicity and immunotoxicity evaluations, biodistribution analysis across multiple species, and detailed characterization of the drug product including potency, purity, and stability parameters. Innovative aspects include the use of advanced AAV engineering for enhanced neurotropism, sophisticated stereotactic delivery techniques for precise targeting, and comprehensive biomarker development for translational endpoints. The significance of this work lies in addressing the critical unmet medical need for disease-modifying therapies in PD, particularly for patients with LRRK2 mutations who currently have no targeted treatment options. Success would establish the foundation for first-in-human clinical trials and potentially transform treatment paradigms for genetic forms of Parkinson's disease.

This experiment directly tests predictions arising from the following hypotheses:

• Partial Neuronal Reprogramming via Modified Yamanaka Cocktail
• Synthetic Biology Rewiring via Orthogonal Receptors
• Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery
• RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery
• CX43 hemichannel engineering enables size-selective mitochondrial transfer

Experimental Protocol

Phase 1: Manufacturing and analytical development (Months 1-6). Produce clinical-grade AAV-LRRK2 vector using established GMP protocols. Conduct comprehensive analytical characterization including vector genome titer, infectious unit determination, residual host cell protein analysis, and endotoxin testing. Develop and validate potency assays measuring LRRK2 knockdown efficiency in relevant cell lines. Phase 2: Pharmacology studies (Months 4-12). Conduct dose-ranging studies in non-human primates (n=24, 4 groups of 6) using stereotactic injection into substantia nigra. Test doses of 1×10^11, 5×10^11, 1×10^12, and 5×10^12 vector genomes. Assess LRRK2 protein reduction, dopaminergic neuron preservation, and motor function using standardized behavioral assessments at 1, 3, 6, and 12 months post-injection. Phase 3: Safety and toxicology (Months 6-18). Perform GLP toxicology studies in non-human primates (n=32) and rodents (n=64) with 6-month treatment and 6-month recovery periods. Monitor clinical observations, hematology, clinical chemistry, histopathology, and immunological responses. Conduct genotoxicity assessment including Ames test and in vivo micronucleus assay. Phase 4: Biodistribution studies (Months 12-20). Evaluate vector distribution in non-human primates (n=18) at multiple timepoints using qPCR analysis of tissues. Assess vector shedding in bodily fluids and environmental release potential. Phase 5: Regulatory preparation (Months 18-24). Compile comprehensive IND package including CMC documentation, preclinical study reports, clinical protocol, and investigator brochure.

Expected Outcomes

• Successful production of clinical-grade AAV-LRRK2 vector meeting FDA specifications with >90% purity, <5 EU/mL endotoxin levels, and vector genome titers ≥1×10^13 vg/mL
• Dose-dependent LRRK2 protein reduction of 40-80% in substantia nigra neurons at 3 months post-injection, with optimal efficacy at 1×10^12 vector genomes dose level
• Preservation of 60-75% dopaminergic neurons compared to <30% in untreated controls in parkinsonian animal models, with statistically significant difference (p<0.001)
• Acceptable safety profile with no treatment-related mortality, minimal inflammatory responses (<2-fold increase in microglial activation), and reversible injection site reactions in <20% of animals
• Vector biodistribution demonstrating >95% localization to injection site with minimal systemic distribution (<0.1% of injected dose detected in peripheral organs)
• Successful FDA pre-IND meeting with agreement on clinical trial design and no major regulatory objections to the proposed development plan

Success Criteria

• • Achievement of ≥50% LRRK2 knockdown in target brain regions with duration ≥6 months demonstrating therapeutic durability
• • No Grade 3 or higher treatment-related adverse events in toxicology studies and no evidence of genotoxicity in standard battery of tests
• • Vector biodistribution showing ≥90% retention at injection site with <1% detection in reproductive organs or germline tissues
• • Demonstration of neuroprotective efficacy with ≥50% preservation of dopaminergic neurons compared to vehicle controls (p<0.01)
• • Successful completion of FDA pre-IND meeting with regulatory alignment on clinical trial design and no requests for additional preclinical studies
• • Manufacturing process capable of producing consistent clinical-grade material meeting all release specifications across ≥3 independent production runs